Autres langues BioCardia, Inc.

Actions

BCDA

US09060U5074

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
0,3766 ^USD	+2,34 %		+4,61 %	-43,30 %

25/04	BioCardia termine le recrutement de la cohorte ouverte de l'essai CardiAMP® Cell Therapy for the Treatment of Chronic Myocardial Ischemia (thérapie cellulaire pour le traitement de l'ischémie myocardique chronique)	CI
27/03	Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25/04
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25/04
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	27/03
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	20/03
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	13/03
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	13/03
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12/03
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12/03
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04/03
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04/03
BioCardia, Inc. announced that it expects to receive $0.874999 million in funding	09/02
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	08/02
BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	08/02
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference	31/01
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders	03/01
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	19/12
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	19/12
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes	18/12
BioCardia, Inc. Announces Expected Cardiamp Heart Failure Japan Approval Based on Pharmaceutical and Medical Device Agency Consultation Minutes	18/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BioCardia, Inc.

Actions

BCDA

US09060U5074

Autres langues

Filtres